Washington, DC—Scientists at Children’s National Medical Center have demonstrated conclusively that a specific protein and its signaling activity are instrumental in myelination and remyelination, processes essential to the creation and repair of the brain’s white matter. This groundbreaking discovery in mouse models points the way to developing treatments or interventions to enhance healthy brain development and/or brain disease repair in children and adults. The paper will be published in the August issue of Nature Neuroscience.
“By understanding the fundamental mechanisms of brain development, we get closer to finding clear instructions to repairing developmental brain disorders and injuries,” said Vittorio Gallo, PhD, Director, Center for Neuroscience Research, Children’s Research Institute at Children’s National Medical Center.
Dr. Gallo and colleagues’ study used mouse models to identify an essential protein and its signaling activity in the processes of myelination and remyelination. These processes are relevant to white matter development and repair. When white matter is injured or defective, the essential functions of information relay are impaired. Underdeveloped white matter or white matter injuries are linked to conditions including mental retardation, cerebral palsy and multiple sclerosis.
“Children’s National Medical Center is the ideal environment for complex research,” said Dr. Gallo. “We work collaboratively with research institutes around the world, and then we walk down the hall to confer with colleagues who are on the front line of direct clinical care. My colleagues in clinical research and care pioneered whole body cooling, which slows down brain damage underway in compromised newborns. Our breakthrough at the level of laboratory research will soon translate to the bedsides where they care for newborns.”
“If we can marry whole body cooling with new approaches that boost the activity of this essential protein, we may be able to slow down injury and enhance myelination,” continued Dr. Gallo. “Some day we may be able to repair brain damage and subsequent affects such as mental retardation, developmental disabilities or other disorders that result from incomplete myelination or white matter damage.”
Myelination in humans begins in utero at around 5 months of gestation and continues throughout the first three years of life, but can be impaired for a number of reasons, most commonly intrauterine infection, reduced or interrupted blood flow (which carries oxygen and nutrients) to the forming infant brain, or perinatal injury. These conditions affect up to 30 percent of preterm babies, many with severe motor and cognitive deficits, such as in patients affected by cerebral palsy.
Remyelination is a natural attempt by the brain to repair damage of the white matter; however the brain does not have the ability to completely repair itself.
Dr. Gallo and colleagues’ work used enhanced epidermal growth factor receptor (EGFR) protein and activity to clearly demonstrate the role that this molecule plays as a catalyst to the natural processes of proliferation and migration of progenitor cells, which are integral to white matter development and repair. By first inserting enhanced EGFR protein and showing enhanced myelination/remyelination, and then using an EGFR protein with reduced biological activity – and showing the decrease in myelination/remyelination – Dr. Gallo and colleagues demonstrate that EGFR protein is an essential ingredient and that its signaling is instrumental in progenitor cell proliferation, migration, and in myelination and functional repair of white matter.
Dr. Gallo’s work reported in this paper specifically demonstrates the following:
Dr. Gallo’s work also reconfirmed that by enhancing EGFR receptor activity on a specific population of progenitor cells (through genetic manipulation), myelination and remyelination can be enhanced. This part of the study builds on earlier work done in collaboration with Nancy Ratner, PhD, Professor in the Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center.
Children's National Medical Center, located in Washington, DC, is a leader in the development of innovative new treatments for childhood illness and injury. Among the top 10 pediatric hospitals in America, Children’s has been serving the nation's children for more than 130 years. Children’s Research Institute, the academic arm of Children’s National Medical Center, encompasses the translational, clinical and community research efforts of the institution. Visit our web site at www.dcchildrens.com.
About Dr. Gallo
Vittorio Gallo, PhD, is an internationally recognized neuroscientist and developmental neurobiologist. He is Director of the Center for Neuroscience Research at Children’s National Medical Center and the Director of the Mental Retardation and Developmental Disabilities Research Center at Children’s, which is supported by the National Institute of Child Health and Human Development (NICHD). Dr. Gallo came to Children’s from the NICHD, where he was Chief of the Section on Molecular and Cellular Neurobiology.
Dr. Gallo holds the Wolf-Pack Chair in Neuroscience, and is Professor of Pediatrics, Pharmacology and Physiology at the George Washington University School of Medicine. Research in Dr. Gallo’s Center focuses on brain development and developmental disabilities. His research is supported by the National Institute of Neurological Disorders and Stroke (NINDS) and by the National Multiple Sclerosis Society.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.